The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sporanox     2-butan-2-yl-4-[4-[4-[4- [[(2S,4S)-2-(2,4...

Synonyms: Canadiol, Hyphanox, Itrizole, Sporanos, Sporonox, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of R 51211


Psychiatry related information on R 51211

  • The scores on the Brief Psychiatric Rating Scale decreased significantly but only by 6% after itraconazole treatment (P < .05); however, the scores on the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale were not changed [4].
  • Barnes Akathisia Rating Scale (BARS) of subjects with CYP2D6*10/*10 in the presence of itraconazole pretreatment was significantly higher than that of subjects with CYP2D6*1/*1 genotype in the period of placebo pretreatment [5].
  • Demonstrating that ketoconazole and itraconazole are reaching the systemic circulation by obtaining serum concentrations may be clinically useful due to the large variability in their absorption and issues of patient compliance which may be seen with these agents [6].
  • Hallucinations associated with itraconazole therapy [7].
  • Consequently, we have used a previously published decision-making algorithm to determine whether clinical pharmacokinetic monitoring of itraconazole is warranted [8].

High impact information on R 51211


Chemical compound and disease context of R 51211


Biological context of R 51211


Anatomical context of R 51211


Associations of R 51211 with other chemical compounds


Gene context of R 51211


Analytical, diagnostic and therapeutic context of R 51211


  1. Oral azole drugs as systemic antifungal therapy. Como, J.A., Dismukes, W.E. N. Engl. J. Med. (1994) [Pubmed]
  2. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. Supparatpinyo, K., Perriens, J., Nelson, K.E., Sirisanthana, T. N. Engl. J. Med. (1998) [Pubmed]
  3. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. Stevens, D.A., Schwartz, H.J., Lee, J.Y., Moskovitz, B.L., Jerome, D.C., Catanzaro, A., Bamberger, D.M., Weinmann, A.J., Tuazon, C.U., Judson, M.A., Platts-Mills, T.A., DeGraff, A.C. N. Engl. J. Med. (2000) [Pubmed]
  4. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Jung, S.M., Kim, K.A., Cho, H.K., Jung, I.G., Park, P.W., Byun, W.T., Park, J.Y. Clin. Pharmacol. Ther. (2005) [Pubmed]
  5. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. Park, J.Y., Shon, J.H., Kim, K.A., Jung, H.J., Shim, J.C., Yoon, Y.R., Cha, I.J., Shin, J.G. Journal of clinical psychopharmacology. (2006) [Pubmed]
  6. Therapeutic drug monitoring of systemic antifungal therapy. Summers, K.K., Hardin, T.C., Gore, S.J., Graybill, J.R. J. Antimicrob. Chemother. (1997) [Pubmed]
  7. Hallucinations associated with itraconazole therapy. Cleveland, K.O., Campbell, J.W. Clin. Infect. Dis. (1995) [Pubmed]
  8. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Buchkowsky, S.S., Partovi, N., Ensom, M.H. Therapeutic drug monitoring. (2005) [Pubmed]
  9. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. Lees, R.S., Lees, A.M. N. Engl. J. Med. (1995) [Pubmed]
  10. Use of terfenadine and contraindicated drugs. Thompson, D., Oster, G. JAMA (1996) [Pubmed]
  11. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. Gupta, S., Kim, J., Gollapudi, S. J. Clin. Invest. (1991) [Pubmed]
  12. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Barbaro, G., Barbarini, G., Calderon, W., Grisorio, B., Alcini, P., Di Lorenzo, G. Gastroenterology (1996) [Pubmed]
  13. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K. Ann. Intern. Med. (2001) [Pubmed]
  14. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. de Gans, J., Portegies, P., Tiessens, G., Eeftinck Schattenkerk, J.K., van Boxtel, C.J., van Ketel, R.J., Stam, J. AIDS (1992) [Pubmed]
  15. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Crane, J.K., Shih, H.T. Am. J. Med. (1993) [Pubmed]
  16. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Bar-Oz, B., Moretti, M.E., Mareels, G., Van Tittelboom, T., Koren, G. Lancet (1999) [Pubmed]
  17. Congestive heart failure associated with itraconazole. Ahmad, S.R., Singer, S.J., Leissa, B.G. Lancet (2001) [Pubmed]
  18. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. Bosque, E. Ann. Intern. Med. (2001) [Pubmed]
  19. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Cardiello, P.G., Samor, T., Burger, D., Hoetelmans, R., Mahanontharit, A., Ruxrungtham, K., Lange, J.M., Cooper, D.A., Phanuphak, P. Antivir. Ther. (Lond.) (2003) [Pubmed]
  20. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Winston, D.J., Emmanouilides, C., Bartoni, K., Schiller, G.J., Paquette, R., Territo, M.C. Blood (2004) [Pubmed]
  21. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Stevens, D.A., Lee, J.Y. Arch. Intern. Med. (1997) [Pubmed]
  22. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Denning, D.W., Tucker, R.M., Hanson, L.H., Hamilton, J.R., Stevens, D.A. Arch. Intern. Med. (1989) [Pubmed]
  23. The KEX2 gene of Candida glabrata is required for cell surface integrity. Bader, O., Schaller, M., Klein, S., Kukula, J., Haack, K., Mühlschlegel, F., Korting, H.C., Schäfer, W., Hube, B. Mol. Microbiol. (2001) [Pubmed]
  24. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. Wark, P.A., Hensley, M.J., Saltos, N., Boyle, M.J., Toneguzzi, R.C., Epid, G.D., Simpson, J.L., McElduff, P., Gibson, P.G. J. Allergy Clin. Immunol. (2003) [Pubmed]
  25. Airborne outbreak of nosocomial Scedosporium prolificans infection. Guerrero, A., Torres, P., Duran, M.T., Ruiz-Díez, B., Rosales, M., Rodriguez-Tudela, J.L. Lancet (2001) [Pubmed]
  26. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Kramer, M.R., Marshall, S.E., Denning, D.W., Keogh, A.M., Tucker, R.M., Galgiani, J.N., Lewiston, N.J., Stevens, D.A., Theodore, J. Ann. Intern. Med. (1990) [Pubmed]
  27. A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Gachotte, D., Pierson, C.A., Lees, N.D., Barbuch, R., Koegel, C., Bard, M. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  28. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. Diabetologia (2003) [Pubmed]
  29. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Patterson, T.F., Kirkpatrick, W.R., White, M., Hiemenz, J.W., Wingard, J.R., Dupont, B., Rinaldi, M.G., Stevens, D.A., Graybill, J.R. Medicine (Baltimore) (2000) [Pubmed]
  30. Itraconazole increases plasma concentrations of quinidine. Kaukonen, K.M., Olkkola, K.T., Neuvonen, P.J. Clin. Pharmacol. Ther. (1997) [Pubmed]
  31. Pharmacokinetics of antifungal agents in onychomycoses. Debruyne, D., Coquerel, A. Clinical pharmacokinetics. (2001) [Pubmed]
  32. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Niemi, M., Backman, J.T., Juntti-Patinen, L., Neuvonen, M., Neuvonen, P.J. British journal of clinical pharmacology. (2005) [Pubmed]
  33. Isolation, characterization, and regulation of the Candida albicans ERG27 gene encoding the sterol 3-keto reductase. Pierson, C.A., Jia, N., Mo, C., Lees, N.D., Sturm, A.M., Eckstein, J., Barbuct, R., Bard, M. Med. Mycol. (2004) [Pubmed]
  34. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Suh, J.W., Koo, B.K., Zhang, S.Y., Park, K.W., Cho, J.Y., Jang, I.J., Lee, D.S., Sohn, D.W., Lee, M.M., Kim, H.S. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. (2006) [Pubmed]
  35. Misleading statements in industry-sponsored meta-analysis of itraconazole. Gøtzsche, P.C., Johansen, H.K. J. Clin. Oncol. (2005) [Pubmed]
  36. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. Chaiwarith, R., Charoenyos, N., Sirisanthana, T., Supparatpinyo, K. AIDS (2007) [Pubmed]
  37. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Lilja, J.J., Backman, J.T., Laitila, J., Luurila, H., Neuvonen, P.J. Clin. Pharmacol. Ther. (2003) [Pubmed]
  38. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Varis, T., Kivistö, K.T., Backman, J.T., Neuvonen, P.J. Clin. Pharmacol. Ther. (2000) [Pubmed]
WikiGenes - Universities